Compounded vs brand name and honestly I cannot tell the difference

Adding the clinical framing, because it changes how the question reads.

Compounding pharmacy customer here with experience relevant to compounded supply.

I've ordered from 2 different compounding pharmacies over the past 2 years. The quality variation is real — purity ranged from 94% to 101% of label claim based on independent Janoshik testing.

My current compounder (a 503B facility) has been consistently 98-101% purity across 10 orders. I pay $133/month vs $1,383 for brand. The savings are substantial and the product is equivalent in my experience.

Re: compounded supply — this applies whether you're using brand or compounded. The clinical principles are the same.

sophie_paris said:

Compounding pharmacy customer here with experience relevant to compounded supply.

Adding a me-too, because a thread of one person's experience is not much use.

sophie_paris said:

Compounding pharmacy customer here with experience relevant to compounded supply.

Price comparison for compounded supply across sources I've used:

I use the 503B option — best balance of quality, cost, and legality. The brand price is insane but insurance can help if you qualify.

sophie_paris said:

Compounding pharmacy customer here with experience relevant to compounded supply.

503A vs 503B compounding pharmacies for compounded supply — this distinction matters enormously:

I strongly recommend 503B facilities. The FDA oversight and cGMP requirements mean more consistent product quality.

tommy_boulder said:

Price comparison for compounded supply across sources I've used: Source Monthly Cost Type Purity Verified Brand (Ozempic) $1055 FDA-approved N/A…

Regarding compounded supply compounding legality: compounding pharmacies can legally produce semaglutide and tirzepatide while these drugs remain on the FDA shortage list. If/when the shortage resolves, the legal landscape may change.

Stay informed. The FDA shortage list is updated regularly. Current status as of my last check: semaglutide partially resolved shortage, tirzepatide still in shortage. This directly impacts compounding availability.